Company’s 36-month beta value is 0.45.Analysts have differing opinions on the stock, with 7 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ATXS is 46.42M, and currently, short sellers hold a 6.79% ratio of that floaft. The average trading volume of ATXS on May 01, 2025 was 333.97K shares.
ATXS) stock’s latest price update
Astria Therapeutics Inc (NASDAQ: ATXS)’s stock price has decreased by -0.19 compared to its previous closing price of 5.16. However, the company has seen a -1.15% decrease in its stock price over the last five trading sessions. businesswire.com reported 2025-04-02 that BOSTON–(BUSINESS WIRE)–Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 43,650 shares of Astria’s common stock on April 1, 2025 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were grante.
ATXS’s Market Performance
Astria Therapeutics Inc (ATXS) has seen a -1.15% fall in stock performance for the week, with a -4.63% decline in the past month and a -31.24% plunge in the past quarter. The volatility ratio for the week is 6.24%, and the volatility levels for the past 30 days are at 9.49% for ATXS. The simple moving average for the last 20 days is 12.85% for ATXS stock, with a simple moving average of -43.17% for the last 200 days.
Analysts’ Opinion of ATXS
Many brokerage firms have already submitted their reports for ATXS stocks, with Cantor Fitzgerald repeating the rating for ATXS by listing it as a “Overweight.” The predicted price for ATXS in the upcoming period, according to Cantor Fitzgerald is $47 based on the research report published on April 29, 2025 of the current year 2025.
JMP Securities, on the other hand, stated in their research note that they expect to see ATXS reach a price target of $26. The rating they have provided for ATXS stocks is “Mkt Outperform” according to the report published on January 31st, 2025.
TD Cowen gave a rating of “Buy” to ATXS, setting the target price at $35 in the report published on July 29th of the previous year.
ATXS Trading at -7.84% from the 50-Day Moving Average
After a stumble in the market that brought ATXS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.14% of loss for the given period.
Volatility was left at 9.49%, however, over the last 30 days, the volatility rate increased by 6.24%, as shares sank -5.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -25.14% lower at present.
During the last 5 trading sessions, ATXS rose by +0.58%, which changed the moving average for the period of 200-days by -55.71% in comparison to the 20-day moving average, which settled at $4.57. In addition, Astria Therapeutics Inc saw -42.39% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ATXS
The total capital return value is set at -0.35. Equity return is now at value -33.52, with -31.58 for asset returns.
Based on Astria Therapeutics Inc (ATXS), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -15.17.
Currently, EBITDA for the company is -94.26 million with net debt to EBITDA at 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.49.
Conclusion
In a nutshell, Astria Therapeutics Inc (ATXS) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
